home / stock / agen / agen quote
Last: | $15.13 |
---|---|
Change Percent: | -0.14% |
Open: | $14.55 |
Close: | $15.13 |
High: | $15.15 |
Low: | $14.1102 |
Volume: | 317,114 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$15.13 | $14.55 | $15.13 | $15.15 | $14.1102 | 317,114 | 07-05-2024 |
$14.53 | $14.33 | $14.53 | $14.92 | $14.21 | 241,232 | 07-04-2024 |
$14.53 | $14.33 | $14.53 | $14.92 | $14.21 | 241,232 | 07-03-2024 |
$14.28 | $16.57 | $14.28 | $16.585 | $14.2 | 674,637 | 07-02-2024 |
$16.69 | $16.75 | $16.69 | $17.99 | $16.35 | 776,641 | 07-01-2024 |
$16.75 | $14.16 | $16.75 | $16.945 | $14.0849 | 1,520,955 | 06-28-2024 |
$14.12 | $14.15 | $14.12 | $14.43 | $13.75 | 288,124 | 06-27-2024 |
$14.21 | $14.9 | $14.21 | $15.14 | $14.17 | 419,282 | 06-26-2024 |
$14.87 | $15.19 | $14.87 | $15.5 | $14.72 | 354,558 | 06-25-2024 |
$15.23 | $14.53 | $15.23 | $15.66 | $14.53 | 533,947 | 06-24-2024 |
$14.56 | $13.57 | $14.56 | $14.68 | $13.33 | 611,806 | 06-21-2024 |
$13.57 | $12.95 | $13.57 | $13.63 | $12.59 | 383,649 | 06-20-2024 |
$12.99 | $13.94 | $12.99 | $14.09 | $12.34 | 1,367,824 | 06-19-2024 |
$12.99 | $13.94 | $12.99 | $14.09 | $12.34 | 1,367,824 | 06-18-2024 |
$14.3 | $15.25 | $14.3 | $15.5475 | $14.0102 | 588,907 | 06-17-2024 |
$15.46 | $15.71 | $15.46 | $16.76 | $15.23 | 423,008 | 06-14-2024 |
$16 | $16.94 | $16 | $17.4 | $15.81 | 520,787 | 06-13-2024 |
$16.92 | $17.19 | $16.92 | $17.59 | $16.62 | 335,230 | 06-12-2024 |
$16.78 | $17.16 | $16.78 | $17.24 | $16.5 | 397,870 | 06-11-2024 |
$17.17 | $16.39 | $17.17 | $17.65 | $16.011 | 495,925 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...